# Belbuca

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/belbuca
Canonical HTML page: https://getfinancebrief.com/entity/belbuca

## Recent coverage (1 stories)

### CRA International and Collegium Pharma Signal Resilience in Q4 2025 Results
2026-02-27 14:49:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CRA International (CRAI) and Collegium Pharmaceutical (COLL) both reported strong Q4 2025 results, highlighting a robust environment for specialized consulting and chronic pain management. While CRAI benefited from record headcount and high utilization in antitrust and litigation, Collegium demonstrated the continued commercial durability of its Belbuca and Xtampza ER franchises.
Full story: https://getfinancebrief.com/story/crai-coll-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.